Intervention

Dasatinib plus quercetin

Source-reviewedGoverned LongevityNext intelligence profile

Evidence reviewed through2026-08-07

Executive intelligence snapshot

Current reviewed view

The overall primary endpoint was negative, while secondary and exploratory signals appeared at earlier time points and in a high-p16 subgroup.

This profile includes 2 reviewed relationship(s) and 2 reviewed source(s).

This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.

Evidence state

Source-reviewed

Evidence reviewed through2026-08-07

Evidence state

What the evidence supports

The overall primary endpoint was negative, while secondary and exploratory signals appeared at earlier time points and in a high-p16 subgroup.

Evidence boundary

Key limitations

The trial did not prove senolysis ineffective; exploratory high-senescent-burden findings and short-term bone-formation changes remain hypothesis-generating.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.

Not established

Key unknowns

Dose, route, population, and outcomes not recorded in this reviewed profile remain unknown.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.

Next evidence milestone

What would change this view?

No specific evidence milestone is recorded yet.

Evidence reviewed through 2026-08-07.

Intelligence connections

Linked company

Mayo Clinic

Company

Tested in